ES / EN
- July 12, 2025 -
No Result
View All Result
OnCubaNews
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors
OnCubaNews
ES / EN
Home Coronavirus

Soberana 02 vaccine candidate starts large-scale production

The country’s most advanced Cuban prototype COVID-19 vaccine is due to enter phase III of clinical trials in March.

by
  • OnCuba Staff
    OnCuba Staff,
  • OnCuba editorial staff
February 21, 2021
in Coronavirus, Cuba
0
Soberana 02 is the most advanced Cuban vaccine candidate to date. Photo: taken from the official Twitter of the Cuban Ministry of Sciences.

Soberana 02 is the most advanced Cuban vaccine candidate to date. Photo: taken from the official Twitter of the Cuban Ministry of Sciences.

The large-scale production of the Cuban Soberana 02 COVID-19 vaccine candidate has started at the National Center for Biopreparations (Biocen), authorities from the BioCubaFarma business group and the Finlay Vaccine Institute confirmed.

It was learned in a note published by the official media on the island that the mass production of this prototype in Biocen’s bioparent plant is due to its upcoming use during phase III of clinical trials, which should begin in March.

The note says that Soberana 02 is the most advanced of the four vaccine candidates that are in different stages of clinical trials, all with positive results at the moment: Soberana 01, Mambisa and Abdala.

The current health emergency being experienced by Cuba and the rest of the planet due to the SARS-CoV-2 virus makes the production of these products a challenge for Cuban science, always complying with quality standards and with sufficient productive capacities, the source specified.

Presidente de #BioCubaFarma junto a otros directivos del sector realiza recorrido por la Planta de Parenterales de @BIOCENCU, donde ya se está produciendo a gran escala la #Soberana02 que se utilizará en el Ensayo Clínico Fase III. #CubaViva pic.twitter.com/G698BRZvYP

— BioCubaFarma (@BioCubaFarma) February 20, 2021

The Cuban biopharmaceutical industry announced that the production of the first batch of 150,000 bulbs of Soberana 02 had concluded and work is already underway on the second group of this vaccine candidate, which began phase II of clinical trials on December 22, 2020, a stage in which around 900 volunteers were involved.

Related Posts

Sandra Sotolongo, co-director of the “inSurGENTES” project, during an activity in the vegetable garden. Photo: Courtesy.

Insurgents, an open-air revolution

July 10, 2025
Private business on Infanta and 23rd Streets, in Vedado, Havana. Photo: AMD.

MSMEs barely growing and their slowdown hinders competition and economic dynamism

July 9, 2025
Entrance to San Juan Park, located east of Santiago.

San Juan Hill: heritage in the attic?

July 6, 2025
Headquarters of the Matanzas People’s Court, where the trial was held. Photo: Matanzas People’s Court/Facebook.

Prosecutor’s Office requests up to 9 years in prison for synthetic drug trafficking in Matanzas

June 30, 2025

This prototype is a conjugate vaccine where the virus antigen, receptor binding domain (RBD), chemically binds to tetanus toxoid, as confirmed by specialized sources.

If all the health protocols are met, Cuba would be one of the first countries in the Latin American and Caribbean region to have a COVID-19 vaccine ready, to begin mass vaccination in the second half of this year.

  • OnCuba Staff
    OnCuba Staff,
  • OnCuba editorial staff
Tags: Cuban vaccine against COVID-19
Previous Post

More than a thousand coronavirus infections in Cuba, number rises again

Next Post

Faces and stories of the Parque de la Fraternidad

OnCuba Staff

OnCuba Staff

OnCuba Staff

OnCuba Staff

Next Post
Parque de la Fraternidad

Faces and stories of the Parque de la Fraternidad

Laboratory

New molecular biology laboratory opens in Guantánamo

New infections

Coronavirus accumulates 300 deaths in Cuba

Leave a Reply Cancel reply

The conversation here is moderated according to OnCuba News discussion guidelines. Please read the Comment Policy before joining the discussion.

Your email address will not be published. Required fields are marked *

Most Read

  • Long jumper Lester Lescay during his participation in the European Team Championships

    Lester Lescay: “I left Cuba because I didn’t want to spend my youth there.”

    18 shares
    Share 7 Tweet 5
  • San Juan Hill: heritage in the attic?

    14 shares
    Share 6 Tweet 4
  • Los Palacios, land of Cuban rice harvested by Vietnamese

    13 shares
    Share 5 Tweet 3
  • Trump reinstates hard-line Cuba embargo as Havana condemns US measure as “criminal”

    31 shares
    Share 12 Tweet 8
  • Life on the razor’s edge: the case of Willliam and Viviana

    9 shares
    Share 4 Tweet 2

Most Commented

  • Photo: Kaloian.

    Private sector and tourism in Cuba. Why not?

    12 shares
    Share 5 Tweet 3
  • About us
  • Work with OnCuba
  • Terms of use
  • Privacy Policy
  • Moderation policy for comments
  • Contact us
  • Advertisement offers

OnCuba and the OnCuba logo are registered® trademarks of Fuego Enterprises, Inc., its subsidiaries or divisions.
OnCuba © by Fuego Enterprises, Inc. All Rights Reserved.

No Result
View All Result
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors

OnCuba and the OnCuba logo are registered® trademarks of Fuego Enterprises, Inc., its subsidiaries or divisions.
OnCuba © by Fuego Enterprises, Inc. All Rights Reserved.

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}